Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep's synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022
SAN DIEGO and CALGARY, AB, May 7, 2021 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.